Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes

Diabetes Care. 2010 May;33(5):1028-30. doi: 10.2337/dc09-1961. Epub 2010 Mar 3.

Abstract

Objective: Endothelial dysfunction is frequently present in individuals with insulin resistance or type 2 diabetes and can be induced by high-fat or high-carbohydrate meals. Because exenatide reduces postprandial glucose and lipid excursions, we hypothesized that it may also improve postprandial endothelial function.

Research design and methods: In a double-blinded randomized crossover design, postprandial endothelial function was examined in 28 individuals with impaired glucose tolerance or recent-onset type 2 diabetes after a single injection of exenatide or placebo given just before a high-fat meal. Endothelial function was determined with peripheral arterial tonometry pre- and postprandially.

Results: Postprandial endothelial function was higher after exenatide compared with placebo (P = 0.0002). In the placebo phase, postprandial change in endothelial function was inversely associated with mean postprandial concentrations of triglycerides (r = -0.62, P = 0.0004). Changes in postprandial triglyceride concentrations explained 64% of exenatide's effect on postprandial endothelial function.

Conclusions: Exenatide ameliorates postprandial endothelial dysfunction after a high-fat meal.

Trial registration: ClinicalTrials.gov NCT00974272.

Publication types

  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adult
  • Age of Onset
  • Aged
  • Cohort Studies
  • Cross-Over Studies
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / metabolism
  • Dietary Fats / administration & dosage
  • Endothelium / drug effects
  • Endothelium / metabolism
  • Exenatide
  • Female
  • Glucose Intolerance / drug therapy*
  • Glucose Intolerance / metabolism
  • Humans
  • Hyperglycemia / drug therapy*
  • Hyperglycemia / metabolism
  • Hypoglycemic Agents / administration & dosage*
  • Male
  • Middle Aged
  • Peptides / administration & dosage*
  • Triglycerides / blood
  • Venoms / administration & dosage*

Substances

  • Dietary Fats
  • Hypoglycemic Agents
  • Peptides
  • Triglycerides
  • Venoms
  • Exenatide

Associated data

  • ClinicalTrials.gov/NCT00974272